Accuray Incorporated (LON:0H8I)
Market Cap | 149.37M |
Revenue (ttm) | 334.66M |
Net Income (ttm) | -1.16M |
Shares Out | n/a |
EPS (ttm) | -0.01 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 36,182 |
Average Volume | 18,147 |
Open | 1.820 |
Previous Close | 1.800 |
Day's Range | 1.781 - 1.930 |
52-Week Range | 1.145 - 2.940 |
Beta | n/a |
RSI | 61.49 |
Earnings Date | Nov 5, 2025 |
About Accuray
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidne... [Read more]
Financial Performance
In 2025, Accuray's revenue was $458.51 million, an increase of 2.68% compared to the previous year's $446.55 million. Losses were -$1.59 million, -89.77% less than in 2024.
Financial numbers in USD Financial StatementsNews

Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
MADISON, Wis. , Sept. 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced today the signing of a memor...
Accuray Incorporated (ARAY) Shareholder/Analyst Call Transcript

Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
New Solution Provides an Unprecedented Set of Tools, Empowering Clinical Teams With Choice and Flexibility to Deliver Adaptive Care—Tailoring Radiotherapy to Each Patient's Unique Needs MADISON, Wis. ...

Accuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025
Event Will Feature Global KOLs Sharing Their Perspectives on the Role of Adaptive Radiotherapy in Radiation Medicine MADISON, Wis. , Sept. 11, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) ...
Accuray Continues To Establish A Disappointing 'Is What It Is' Story

Accuray Q4 Revenue Hits $128 Million
Accuray targets $471M–$485M revenue in fiscal 2026 as service business growth offsets geopolitical headwinds
Accuray Incorporated 2025 Q4 - Results - Earnings Call Presentation
Accuray Incorporated (ARAY) Q4 2025 Earnings Call Transcript

Accuray (ARAY) Q4 2025 Earnings Call Transcript
Accuray GAAP EPS of $0.01 misses by $0.01, revenue of $127.54M beats by $3.07M

Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results
Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the...
Accuray Q4 2025 Earnings Preview
A Glimpse of Accuray's Earnings Potential
Accuray (NASDAQ: ARAY) will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Accuray to report an e...

Accuray to Report Fourth Quarter Fiscal 2025 Financial Results on August 13, 2025
MADISON, Wis. , July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended June 30, 2025, during a conference cal...
Accuray restructures debt, secures new $190M financing; shares down

Accuray Announces Convertible Notes Exchange and Refinancing of Existing Credit Facilities
MADISON, Wis. , June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous pote...

Accuray to Participate in the Jefferies Global Healthcare Conference 2025
MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.

Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated ...

Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System
Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis. , May 5, 2025 /PRNewswire/ -- Accura...
Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade)
Accuray outlines Q4 revenue guidance with $10M-$15M impact from China tariffs
Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript
Accuray Incorporated (NASDAQ:ARAY) Q3 2025 Earnings Call April 30, 2025 4:30 PM ETCompany ParticipantsJesse Chew - Chief Legal OfficerSuzanne Winter -...

Accuray Reports Fiscal 2025 Third Quarter Financial Results
MADISON, Wis. , April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2025.
Insights Ahead: Accuray's Quarterly Earnings
Accuray (NASDAQ: ARAY) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...